» Articles » PMID: 33708195

CpG Adjuvant in Allergen-Specific Immunotherapy: Finding the Sweet Spot for the Induction of Immune Tolerance

Overview
Journal Front Immunol
Date 2021 Mar 12
PMID 33708195
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Prevalence and incidence of IgE-mediated allergic diseases have increased over the past years in developed and developing countries. Allergen-specific immunotherapy (AIT) is currently the only curative treatment available for allergic diseases that has long-term efficacy. Although AIT has been proven successful as an immunomodulatory therapy since its beginnings, it still faces several unmet needs and challenges today. For instance, some patients can experience severe side effects, others are non-responders, and prolonged treatment schedules can lead to lack of patient adherence and therapy discontinuation. A common strategy to improve AIT relies on the use of adjuvants and immune modulators to boost its effects and improve its safety. Among the adjuvants tested for their clinical efficacy, CpG oligodeoxynucleotide (CpG-ODN) was investigated with limited success and without reaching phase III trials for clinical allergy treatment. However, recently discovered immune tolerance-promoting properties of CpG-ODN place this adjuvant again in a prominent position as an immune modulator for the treatment of allergic diseases. Indeed, it has been shown that the CpG-ODN dose and concentration are crucial in promoting immune regulation through the recruitment of pDCs. While low doses induce an inflammatory response, high doses of CpG-ODN trigger a tolerogenic response that can reverse a pre-established allergic milieu. Consistently, CpG-ODN has also been found to stimulate IL-10 producing B cells, so-called B regulatory cells (Bregs). Accordingly, CpG-ODN has shown its capacity to prevent and revert allergic reactions in several animal models showing its potential as both preventive and active treatment for IgE-mediated allergy. In this review, we describe how CpG-ODN-based therapies for allergic diseases, despite having shown limited success in the past, can still be exploited further as an adjuvant or immune modulator in the context of AIT and deserves additional attention. Here, we discuss the past and current knowledge, which highlights CpG-ODN as a potential adjuvant to be reevaluated for the enhancement of AIT when used in appropriate conditions and formulations.

Citing Articles

Explore Alteration of Lung and Gut Microbiota in a Murine Model of OVA-Induced Asthma Treated by CpG Oligodeoxynucleotides.

Wang Q, Ji J, Xiao S, Wang J, Yan X, Fang L J Inflamm Res. 2025; 18():445-461.

PMID: 39816955 PMC: 11734504. DOI: 10.2147/JIR.S487916.


Respiratory Flora Intervention: A New Strategy for the Prevention and Treatment of Occupationally Related Respiratory Allergy in Healthcare Workers.

Gao L, Chen X, Jiang Z, Zhu J, Wang Q Microorganisms. 2025; 12(12.

PMID: 39770855 PMC: 11728507. DOI: 10.3390/microorganisms12122653.


Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives.

Ren D, Xiong S, Ren Y, Yang X, Zhao X, Jin J Comput Struct Biotechnol J. 2024; 23:1833-1843.

PMID: 38707540 PMC: 11066472. DOI: 10.1016/j.csbj.2024.04.054.


Novel adjuvants in allergen-specific immunotherapy: where do we stand?.

Lin Y, Zimmermann J, Schulke S Front Immunol. 2024; 15:1348305.

PMID: 38464539 PMC: 10920236. DOI: 10.3389/fimmu.2024.1348305.


Evaluation of different types of adjuvants in a malaria transmission-blocking vaccine.

Yu X, Min H, Yao S, Yao G, Zhang D, Zhang B Int Immunopharmacol. 2024; 131:111817.

PMID: 38460299 PMC: 11090627. DOI: 10.1016/j.intimp.2024.111817.


References
1.
Brugnolo F, Sampognaro S, Liotta F, Cosmi L, Annunziato F, Manuelli C . The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. J Allergy Clin Immunol. 2003; 111(2):380-8. DOI: 10.1067/mai.2003.102. View

2.
Klaschik S, Tross D, Shirota H, Klinman D . Short- and long-term changes in gene expression mediated by the activation of TLR9. Mol Immunol. 2009; 47(6):1317-24. PMC: 2830361. DOI: 10.1016/j.molimm.2009.11.014. View

3.
Obermeier F, Dunger N, Deml L, Herfarth H, Scholmerich J, Falk W . CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol. 2002; 32(7):2084-92. DOI: 10.1002/1521-4141(200207)32:7<2084::AID-IMMU2084>3.0.CO;2-Q. View

4.
Sel S, Wegmann M, Sel S, Bauer S, Garn H, Alber G . Immunomodulatory effects of viral TLR ligands on experimental asthma depend on the additive effects of IL-12 and IL-10. J Immunol. 2007; 178(12):7805-13. DOI: 10.4049/jimmunol.178.12.7805. View

5.
Gelman A, LaRosa D, Zhang J, Walsh P, Choi Y, Sunyer J . The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation. Immunity. 2006; 25(5):783-93. PMC: 2840381. DOI: 10.1016/j.immuni.2006.08.023. View